Figure 2 Serum Tim-3 was elevated in HCC patients with poor outcomes. (A) Distribution of serum Tim-3 in HCC patients who had distinct progression after receiving initial TACE treatment, in the training set. (B) Proportion of progression in HCC patients with low and high serum Tim-3 levels after receiving initial TACE treatment, in the training set. (C) Distribution of serum Tim-3 in HCC patients who died vs those who survived after receiving initial TACE treatment, in the training set. (D) Proportion of death in HCC patients with low and high serum Tim-3 levels after receiving initial TACE treatment, in the training set. (E) Distribution of serum Tim-3 in HCC patients who died vs those who survived after receiving initial TACE treatment, in the validation set. (F) Proportion of progression in HCC patients with low and high serum Tim-3 levels after receiving initial TACE treatment, in the validation set. (G) Distribution of serum Tim-3 in HCC patients who died vs those who survived after receiving initial TACE treatment, in the validation set. (H) Proportion of death in HCC patients with low and high serum Tim-3 levels after receiving initial TACE treatment, in the validation set. HCC – hepatocellular carcinoma; sTIM3 – serum Tim-3; TACE – transcatheter arterial chemoembolization; Tim-3 – T cell immunoglobulin and mucin domain 3.